Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck CancerGlobeNewsWire • 04/08/21
Immutep Announces European Patent Grant For LAG525 Antibody In Combination TherapyGlobeNewsWire • 04/07/21
Immutep To Participate In A Fireside Chat At The Inaugural M Vest And Maxim Group Emerging Growth Virtual ConferenceGlobeNewsWire • 03/17/21
Immutep's Lead Candidate To Be Tested In Combination With Keytruda In Second Head & Neck Cancer StudyBenzinga • 03/16/21
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck CancerGlobeNewsWire • 03/16/21
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 StudyGlobeNewsWire • 01/07/21
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway InhibitorGlobeNewsWire • 12/29/20
Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First DaySeeking Alpha • 12/13/20
Immutep shares soar 190% on positive results in trial of breast cancer treatmentMarket Watch • 12/10/20
Immutep's Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer StudyGlobeNewsWire • 12/09/20
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast CancerGlobeNewsWire • 12/09/20
Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical DevelopmentGlobeNewsWire • 11/18/20